Type I includes low-grade serous carcinoma, mucinous carcinoma, low-grade endometrioid carcinoma and clear cell carcinoma, which tend to be low-grade neoplasms with the mutations of BRAF, KRAS and PTEN; whereas type II is composed of high-grade serous carcinoma, high-grade endometrioid carcinoma and undifferentiated carcinoma which are high-grade neoplasms with high human leukocyte antigen-G (HLA-G) expression and TP53 mutation as markers. This evidence concerns the gene HLA-G and serous adenocarcinoma.